PharmaShots Weekly Snapshots (October 21 – October 25, 2024)
This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, Biosimilars & Biotech. Check out our full report below:
Merck and Gilead Highlight the P-II Study Data of Islatravir Plus Lenacapavir in Virologically Suppressed People with HIV at IDWeek 2024
Read More: Merck and Gilead
Roche Reports 1-Year Data from P-IV (ELEVATUM) Study of Vabysmo (Faricimab) in Patients with Diabetic Macular Edema (DME)
Read More: Roche
Alto Neuroscience’s P-IIb Trial of ALTO-100 for Major Depressive Disorder Couldn’t Achieve its Primary Endpoint
Read More: Alto Neuroscience
Hope Medicine Reports the Data from P-II Trial of HMI-115 for Treating Endometriosis
Read More: Hope Medicine
Alkeus Pharmaceuticals Reports Topline Results from SAGA Trial of Gildeuretinol (ALK-001) for Geographic Atrophy Secondary to Age-Related Macular Degeneration
Read More: Alkeus Pharmaceuticals
Zai Lab Highlights the Data from P-Ia/Ib Trial of ZL-1310 for Treating Extensive-Stage Small Cell Lung Cancer at ENA Symposium 2024
Read More: Zai Lab
Abbott Commences New Clinical Trial to Enhance Patient Outcomes in Advanced Heart Failure
Read More: Abbott
EyePoint Pharmaceuticals Reports the First Patient Dosing in P-III (LUGANO) Study of Duravyu to Treat Wet Age-Related Macular Degeneration
Read More: EyePoint Pharmaceuticals
AbbVie Reports the US FDA’s Approval of Botox Cosmetic (OnabotulinumtoxinA) for Moderate to Severe Vertical Bands Connecting the Jaw and Neck
Read More: AbbVie
AstraZeneca and Ionis’ Wainzua (Eplontersen) Receives the CHMP’s Positive Opinion to Treat Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy
Read More: AstraZeneca and Ionis
Astellas Reports the US FDA’s Approval of Vyloy (Zolbetuximab-clzb) to Treat Advanced G/GEJ Cancer
Read More: Astellas
BeiGene Reports the CHMP’s Positive Opinions for Tevimbra as a 1L Treatment of G/GEJ Cancer and Esophageal Squamous Cell Carcinoma
Read More: BeiGene
Adcentrx Therapeutics Reports the US FDA’s IND Clearance of ADRX-0405 to Treat Advanced Solid Tumors
Read More: Adcentrx Therapeutics
Eli Lilly Reports the MHRA’s Approval of Kisunla (Donanemab) to Treat Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease
Read More: Eli Lilly
HiberCell’s HC-7366 Gains the US FDA’s Fast Track Designation for Treating Acute Myeloid Leukemia (AML)
Read More: HiberCell
Merck Reports EC’s Approval of Keytruda for Two New Indications in Gynecologic Cancers
Read More: Merck
Accent Therapeutics Receives the US FDA’s IND Approval of ATX-559 for Treating Breast Cancer
Read More: Accent Therapeutics
Angelini Pharma Join Forces with Cureverse to Develop and Commercialize CV-01 for Brain Health
Read More: Angelini Pharma and Cureverse
Avacta Therapeutics Collaborates with Tempus AI to Commence AI-Driven Drug Development in Oncology
Read More: Avacta Therapeutics and Tempus AI
GSK Enters into a 5-Year Partnership with Cambridge University to Address Kidney and Respiratory Diseases
Read More: GSK
Telix Spins Off Rhine Pharma to Broaden Global Radiopharmaceutical Reach
Read More: Telix
Eccogene Reports the First Patient Dosing with ECC5004/AZD5004 in P-IIb Trial of Obesity and T2D, Triggering $60M Milestone from AstraZeneca
Read More: Eccogene and AstraZeneca
EydisBio Receives $0.5M Grant to Support the Development of TAK1 Inhibitor Program for Alzheimer's Disease
Read More: EydisBio
AbbVie Inks Pact with Gedeon Richter to Discover and Develop Novel Targets for Neuropsychiatric Conditions
Read More: AbbVie and Gedeon Richter
Dyno Therapeutics Collaborates with Roche to Develop AAV Gene Therapy Vectors for Neurological Diseases
Read More: Dyno Therapeutics and Roche
Teal Health Reports the Regulatory Submission of Teal Wand to the US FDA for Cervical Cancer Screening
Read More: Teal Health
Ocuphire Pharma to Acquire Opus Genetics
Read More: Ocuphire Pharma
Dong-A ST Receives the CHMP’s Positive Opinion for Imuldosa (Biosimilar, Stelara)
Read More: Dong-A ST
Alvotech and Teva Reports the US FDA’s Approval for the Additional Presentation of Selarsdi (Biosimilar, Stelara)
Read More: Alvotech and Teva
Poseida Therapeutics to Feature Non-Clinical Data of P-KLKB1-101 for Treating Hereditary Angioedema at ACAAI 2024
Read More: Poseida Therapeutics
Related Post: PharmaShots Weekly Snapshots (October 14 – October 18, 2024)
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.